Gentian Diagnostics ASA

As of June 30, 2026, Gentian Diagnostics ASA carries a market capitalization of 527.14M, placing it among publicly traded companies globally. Its enterprise value stands at 464.61M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Gentian Diagnostics ASA's next confirmed earnings release is scheduled for February 18, 2027.

As of June 30, 2026, Gentian Diagnostics ASA has 15.46M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.86, and the price-to-book ratio stands at 2.89.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 464.61M versus a market cap of 527.14M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Gentian Diagnostics ASA maintains a current ratio of 7.43, meaning it holds 7.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.20, indicating elevated leverage, while an interest coverage ratio of -1.19 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Gentian Diagnostics ASA posted a negative return on equity (ROE) of -7.44, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -6.25, reflecting losses generated across the asset base. The company generates approximately 2.92M in revenue per employee across its workforce of 63.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.64 indicates how many times Gentian Diagnostics ASA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Gentian Diagnostics ASA recorded 2.71M in income tax expense. The company reported a pretax loss of -11.65M and -14.37M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 8, 2026, Gentian Diagnostics ASA's stock has declined approximately 28.68% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Gentian Diagnostics ASA generated 183.85M in revenue and converted that into -14.37M in net income, yielding earnings per share of -0.93. EBITDA reached -4.93M, while operating income came in at -14.02M.

As of June 30, 2026, Gentian Diagnostics ASA holds 79.34M in cash and equivalents against 16.81M in total debt, resulting in a net debt position of -79.34M. Total book value stands at 182.70M, with working capital of 154.21M providing operational flexibility.

Gentian Diagnostics ASA produced 11.27M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -7.44M in capital expenditures, free cash flow totaled 3.83M - equivalent to 0.25 per share.

Over the twelve months ended June 30, 2026, Gentian Diagnostics ASA posted a gross margin of 52.76, reflecting its pricing power and cost economics. The operating margin of -7.62 and net profit margin of -7.82 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Gentian Diagnostics ASA paid dividends of 1.00 per share. The dividend payout ratio of -107.49 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 0.73, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.65, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Gentian Diagnostics ASA shareholders.

As of June 30, 2026, Gentian Diagnostics ASA has an Altman Z-Score of 8.33, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.